José Baselga is the physician-in-chief and chief medical officer at Memorial Sloan Kettering Cancer Center (MSKCC) and professor of medicine at Weil Cornell Medical College in New York City. His long-standing research interests are in the development of targeted agents for the therapy of breast cancer and in studying strategies to overcome mechanisms of resistance. He conducted the initial clinical trials with the monoclonal antibodies cetuximab and trastuzumab and is leading the clinical development of several new agents including pertuzumab, everolimus, and PI3K inhibitors. His main focus in the laboratory and in the clinic is in the area of novel anti-HER2 agents, in the identification of mechanisms of resistance to anti-HER2 agents, and therapeutic approaches to target the PI3K pathway. He is also leading a number of neoadjuvant trials in breast cancer and has been at the forefront of developing biomarker-based early and translational clinical trials. He lead the two large phase III studies with pertuzumab in HER2+ and everolimus in ER+ breast cancer that resulted in the approval of these two agents for the therapy of patients with breast cancer. He is currently leading the clinical development of Pi3Kα inhibitors and novel estrogen receptor degrading agents in breast cancer.
Dr. Baselga is past president of ESMO and president of AACR and a past member of the board of directors of AACR and ASCO. Dr. Baselga has received a number of awards including a Young Investigator Award (1992) and a Career Development Award from ASCO (1994), Elected Member of the American Society of Clinical Investigation (2004), AACR-Rosenthal Family Foundation Award (2008), King James I Award (2008), Joseph Martin Award (2012), the EACR Mike Price Gold Medal (2012), Elected Member of the Association of American Physicians (2014), Elected Member of the AACR Academy (2014), and Elected Member of the Institute of Medicine of the National Academies (2014). He is a past member of the Editorial Boards of Cancer Cell, Journal of Clinical Oncology, and Clinical Cancer Research, and he is the founding editor-in-chief on the new AACR flagship journal Cancer Discovery. Dr. Baselga has published over 350 peer-reviewed articles.
Dr. Baselga received his M.D. and Ph.D. degrees from the Universidad Autonoma of Barcelona. He completed a fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center in New York. From 1996 to 2010 he was the chairman of the Medical Oncology Service and founding director of the Vall d’Hebron Institute of Oncology (VHIO) at the Vall d'Hebron University Hospital in Barcelona, Spain. From 2010 to 2012 he was the chief of the division of hematology/oncology and associate director of the Massachusetts General Hospital Cancer Center in Boston and professor of medicine at Harvard Medical School.
"I am enthusiastic about joining the Professional Advisory Board of Breastcancer.org," he says. "If we want to defeat this disease, nothing is more important than patient information and society awareness. Breastcancer.org is ideally suited to be a great tool for patients and the community."